434
Participants
Start Date
July 21, 2020
Primary Completion Date
June 23, 2022
Study Completion Date
May 18, 2023
FYB203 (Proposed aflibercept biosimilar)
Patients will receive 1 IVT injection of FYB203 every 4 weeks for the first 3 consecutive doses, followed by 1 IVT injection every 8 weeks through study completion.
Eylea® (Aflibercept)
Patients will receive 1 IVT injection of Eylea® every 4 weeks for the first 3 consecutive doses, followed by 1 IVT injection every 8 weeks through study completion.
Research Site, Sofia
Research Site, Stara Zagora
Research Site, Hradec Králové
Research Site, Ostrava
Research Site, Pardubice
Research Site, Prague
Research Site, Sokolov
Research Site, Budapest
Research Site, Debrecen
Research Site, Pécs
Research Site, Szeged
Research Site, Székesfehérvár
Research Site, Tatabánya
Research Site, Zalaegerszeg
Research Site, Haifa
Research Site, Jerusalem
Research Site, Kfar Saba
Research Site, Petah Tikva
Research Site, Rehovot
Research Site, Rishon LeZiyyon
Research Site, Tel Aviv
Research Site, Bologna
Research Site, Florence
Research Site, Milan
Research Site, Roma
Research Site, Rozzano
Research Site, Udine
Research Site, Akita
Research Site, Amagasaki
Research Site, Asahikawa
Research Site, Chiyoda City
Research Site, Chūō
Research Site, Fukuoka
Research Site, Fukushima
Research Site, Hamamatsu
Research Site, Himeji
Research Site, Hirakata
Research Site, Kita-ku
Research Site, Kurume
Research Site, Meguro City
Research Site, Nagasaki
Research Site, Nagoya
Research Site, Sapporo
Research Site, Shinjuku-Ku
Research Site, Suita
Research Site, Toride
Research Site, Yokosuka
Research Site, Bielsko-Biala
Research Site, Bydgoszcz
Research Site, Krakow
Research Site, Lodz
Research Site, Olsztyn
Research Site, Tarnów
Research Site, Warsaw
Research Site, Chelyabinsk
Research Site, Kazan'
Research Site, Moscow
Research Site, Novosibirsk
Research Site, Saint Petersburg
Research Site, Kharkiv
Research Site, Kherson
Research Site, Kropyvnytskyi
Research Site, Lutsk
Research Site, Odesa
Research Site, Poltava
Research Site, Zaporizhzhya
Bioeq GmbH
INDUSTRY